{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T09:19:58Z","timestamp":1794561598725,"version":"4.9.1"},"reference-count":121,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.critrevonc.2026.105449","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T23:35:54Z","timestamp":1782257754000},"page":"105449","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Targeted knockdown: siRNA delivery to lung cancer via mesoporous silica nanoparticles"],"prefix":"10.1016","volume":"226","author":[{"given":"Maitreyee","family":"Mukherjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnab K.","family":"Maiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumen","family":"Dhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumya","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2246-0107","authenticated-orcid":false,"given":"Aparna","family":"Datta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105449_bib1","doi-asserted-by":"crossref","first-page":"16213","DOI":"10.3390\/ijms242216213","article-title":"Non-coding RNAs in human cancer and other diseases: overview of the diagnostic potential","volume":"24","author":"Be\u0148a\u010dka","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105449_bib2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jconrel.2010.12.017","article-title":"Comparative in vivo study of poly(ethylene imine)\/siRNA complexes for pulmonary delivery in mice","volume":"151","author":"Beyerle","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.critrevonc.2026.105449_bib3","article-title":"Mesoporous silica nanoparticles in smart drug delivery and siRNA precision therapy for cancer: nanomedicine\u2019s new frontier","volume":"110","author":"Bhattacharya","year":"2025","journal-title":"J. Drug. Deliv. Sci. Technol."},{"key":"10.1016\/j.critrevonc.2026.105449_bib4","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1002\/cmdc.201100259","article-title":"Hydrophobic oxime ethers: a versatile class of pDNA and siRNA transfection lipids","volume":"6","author":"Biswas","year":"2011","journal-title":"ChemMedChem"},{"key":"10.1016\/j.critrevonc.2026.105449_bib5","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"18","key":"10.1016\/j.critrevonc.2026.105449_bib6","doi-asserted-by":"crossref","first-page":"8706","DOI":"10.7150\/thno.57004","article-title":"Smart magnetic resonance imaging-based theranostics for cancer","volume":"11","author":"Brito","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.critrevonc.2026.105449_bib7","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nrc3775","article-title":"Non-small-cell lung cancers: a heterogeneous set of diseases","volume":"14","author":"Chen","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105449_bib8","article-title":"Functional materials for subcellular targeting strategies in cancer therapy: progress and prospects","volume":"37","author":"Cheng","year":"2025","journal-title":"Adv. Mater."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105449_bib9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1158\/1535-7163.MCT-23-0915","article-title":"A Novel Lipid Nanoparticle NBF-006 Encapsulating Glutathione S-Transferase P siRNA for the Treatment of KRAS-Driven Non\u2013small Cell Lung Cancer","volume":"24","author":"Cina","year":"2025","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2026.105449_bib10","article-title":"Tumor redox heterogeneity-responsive nanoparticles for enhanced antitumor efficacy through combining chemo\/chemodynamic therapy","volume":"10","author":"Cui","year":"2025","journal-title":"Int. J. Pharm. X"},{"key":"10.1016\/j.critrevonc.2026.105449_bib11","doi-asserted-by":"crossref","DOI":"10.7759\/cureus.13371","article-title":"Pancoast tumor as the initial presentation of a metastatic colon adenocarcinoma","author":"Cunha","year":"2021","journal-title":"Cureus"},{"issue":"1-2","key":"10.1016\/j.critrevonc.2026.105449_bib12","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ijpharm.2015.01.035","article-title":"Biological stimuli-responsive cyclodextrin-based host\u2013guest nanosystems for cancer therapy","volume":"483","author":"Dan","year":"2015","journal-title":"Int. J. Pharm."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105449_bib13","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.toxlet.2014.01.009","article-title":"Assessment of drug delivery and anticancer potentials of nanoparticles-loaded siRNA targeting STAT3 in lung cancer, in vitro and in vivo","volume":"225","author":"Das","year":"2014","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.critrevonc.2026.105449_bib14","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1021\/mp900015y","article-title":"The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic","volume":"6","author":"Davis","year":"2009","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.critrevonc.2026.105449_bib15","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1080\/17435889.2024.2348438","article-title":"Mesoporous silica nanoparticles: a versatile carrier platform in lung cancer management","volume":"19","author":"Dhingra","year":"2024","journal-title":"Nanomedicine"},{"key":"10.1016\/j.critrevonc.2026.105449_bib16","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2217\/nnm.13.217","article-title":"Polyethyleneimine-functionalized iron oxide nanoparticles for systemic siRNA delivery in experimental arthritis","volume":"9","author":"Duan","year":"2014","journal-title":"Nanomedicine"},{"key":"10.1016\/j.critrevonc.2026.105449_bib17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12645-024-00250-w","article-title":"Mesoporous silica nanotechnology: promising advances in augmenting cancer theranostics","volume":"15","author":"Dutta Gupta","year":"2024","journal-title":"Cancer Nanotechnol."},{"key":"10.1016\/j.critrevonc.2026.105449_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.envres.2023.117263","article-title":"Nano-scale delivery systems for siRNA delivery in cancer therapy: new era of gene therapy empowered by nanotechnology","volume":"239","author":"Ebrahimi","year":"2023","journal-title":"Environ. Res."},{"key":"10.1016\/j.critrevonc.2026.105449_bib19","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.2147\/IJN.S213974","article-title":"Hyaluronic acid-modified mesoporous silica-coated superparamagnetic Fe3O4 nanoparticles for targeted drug delivery","volume":"14","author":"Fang","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.critrevonc.2026.105449_bib20","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/mt.2013.291","article-title":"Delivery of therapeutic siRNA to the lung endothelium via novel lipoplex formulation DACC","volume":"22","author":"Fehring","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.critrevonc.2026.105449_bib21","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202203669","article-title":"Lipid nanoparticle technologies for nucleic acid delivery: a nanoarchitectonics perspective","volume":"32","author":"Ferhan","year":"2022","journal-title":"Adv. Funct. Mater."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105449_bib22","doi-asserted-by":"crossref","DOI":"10.1038\/srep03325","article-title":"A novel platform to enable inhaled naked RNAi medicine for lung cancer","volume":"3","author":"Fujita","year":"2013","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2026.105449_bib23","doi-asserted-by":"crossref","first-page":"e110","DOI":"10.1038\/mtna.2013.29","article-title":"Combination of siRNA-directed Gene Silencing With Cisplatin Reverses Drug Resistance in Human Non-small Cell Lung Cancer","volume":"2","author":"Ganesh","year":"2013","journal-title":"Mol. Ther. - Nucleic Acids"},{"key":"10.1016\/j.critrevonc.2026.105449_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113953","article-title":"Mesoporous silica nanoparticles for pulmonary drug delivery","volume":"177","author":"Garc\u00eda-Fern\u00e1ndez","year":"2021","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.critrevonc.2026.105449_bib25","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/s41467-018-03099-x","article-title":"Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors","volume":"9","author":"George","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105449_bib26","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1038\/sj.leu.2404878","article-title":"Effective treatment of leukemic cell lines with wt1 siRNA","volume":"21","author":"Glienke","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2026.105449_bib27","doi-asserted-by":"crossref","first-page":"701","DOI":"10.3390\/molecules26030701","article-title":"Recent advances in the development of exogenous dsRNA for the induction of RNA interference in cancer therapy","volume":"26","author":"Golubeva","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.critrevonc.2026.105449_bib28","first-page":"1447","article-title":"siRNA-mediated MDM2 inhibition sensitizes human lung cancer A549 cells to radiation","volume":"30","author":"Guo","year":"2007","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105449_bib29","doi-asserted-by":"crossref","DOI":"10.1093\/nsr\/nwac006","article-title":"Construction of nanocarriers based on nucleic acids and their applications in nanobiology delivery systems","volume":"9","author":"Guo","year":"2022","journal-title":"Natl. Sci. Rev."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105449_bib30","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/cgt.2012.31","article-title":"Prevention of tumor growth by needle-free jet injection of anti-C7orf24 siRNA","volume":"19","author":"Hama","year":"2012","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.critrevonc.2026.105449_bib31","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1038\/ncomms4261","article-title":"Transdifferentiation of lung adenocarcinoma in mice with Lkb1 deficiency to squamous cell carcinoma","volume":"5","author":"Han","year":"2014","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105449_bib32","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3390\/nano12030457","article-title":"Review on Nanoparticles and Nanostructured Materials: Bioimaging, Biosensing, Drug Delivery, Tissue Engineering, Antimicrobial, and Agro-Food Applications","volume":"12","author":"Harish","year":"2022","journal-title":"Nanomaterials"},{"key":"10.1016\/j.critrevonc.2026.105449_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13071009","article-title":"Clinical advances of siRNA-based nanotherapeutics for cancer treatment","volume":"13","author":"Hattab","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.critrevonc.2026.105449_bib34","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3109\/08982104.2014.992024","article-title":"siRNA delivery to lung-metastasized tumor by systemic injection with cationic liposomes","volume":"25","author":"Hattori","year":"2015","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.critrevonc.2026.105449_bib35","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1021\/acs.bioconjchem.5b00184","article-title":"Multifunctional envelope-type nano device: evolution from nonselective to active targeting system","volume":"26","author":"Hayashi","year":"2015","journal-title":"Bioconjug Chem."},{"key":"10.1016\/j.critrevonc.2026.105449_bib36","first-page":"2293","article-title":"Suppression of lung cancer progression by biocompatible glycerol triacrylate-spermine-mediated delivery of shAkt1","volume":"7","author":"Hong","year":"2012","journal-title":"Int J Nanomedicine"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105449_bib37","doi-asserted-by":"crossref","first-page":"e77121","DOI":"10.1371\/journal.pone.0077121","article-title":"Knockdown of the Sodium-Dependent Phosphate Co-Transporter 2b (NPT2b) Suppresses Lung Tumorigenesis","volume":"8","author":"Hong","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.critrevonc.2026.105449_bib38","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.3390\/pharmaceutics14081586","article-title":"Nanoparticles-based strategies to improve the delivery of therapeutic small interfering RNA in precision oncology","volume":"14","author":"Huang","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.critrevonc.2026.105449_bib39","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.200247","article-title":"Progress towards non-small-cell lung cancer models that represent clinical evolutionary trajectories","volume":"11","author":"Hynds","year":"2021","journal-title":"Open. Biol."},{"key":"10.1016\/j.critrevonc.2026.105449_bib40","doi-asserted-by":"crossref","first-page":"9529","DOI":"10.1007\/s11033-023-08749-y","article-title":"Advances in siRNA delivery approaches in cancer therapy: challenges and opportunities","volume":"50","author":"Isazadeh","year":"2023","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.critrevonc.2026.105449_bib41","doi-asserted-by":"crossref","first-page":"6088","DOI":"10.3390\/ijms20236088","article-title":"siRNA conjugated nanoparticles\u2014a next generation strategy to treat lung cancer","volume":"20","author":"Itani","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105449_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.115115","article-title":"Silica nanoparticles: a review of their safety and current strategies to overcome biological barriers","volume":"203","author":"Janjua","year":"2023","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.critrevonc.2026.105449_bib43","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1158\/2159-8290.CD-16-0127","article-title":"Role of KEAP1 \/ NRF2 and TP53 mutations in lung squamous cell carcinoma development and radiation resistance","volume":"7","author":"Jeong","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105449_bib44","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13256-017-1223-5","article-title":"A rare presentation of myxofibrosarcoma as a Pancoast tumor: a case report","volume":"11","author":"Jevremovic","year":"2017","journal-title":"J. Med. Case Rep."},{"key":"10.1016\/j.critrevonc.2026.105449_bib45","doi-asserted-by":"crossref","first-page":"676","DOI":"10.3390\/pharmaceutics13050676","article-title":"Targeted RNAi of BIRC5\/SUrvivin Using Antibody-conjugated Poly(propylene Imine)-based Polyplexes Inhibits Growth of PSCA-positive tumors","volume":"13","author":"Jugel","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.critrevonc.2026.105449_bib46","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.3390\/pharmaceutics14112520","article-title":"siRNA functionalized lipid nanoparticles (LNPs) in management of diseases","volume":"14","author":"Kalita","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.critrevonc.2026.105449_bib47","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature12634","article-title":"Mutational landscape and significance across 12 major cancer types","volume":"502","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105449_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.onano.2023.100195","article-title":"Theranostic siRNA loaded mesoporous silica nanoplatforms: a game changer in gene therapy for cancer treatment","volume":"15","author":"Kanungo","year":"2024","journal-title":"OpenNano"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105449_bib49","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-13-338","article-title":"Sticky siRNAs targeting survivin and cyclin B1 exert an antitumoral effect on melanoma subcutaneous xenografts and lung metastases","volume":"13","author":"Kedinger","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2026.105449_bib50","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.3390\/pharmaceutics15051432","article-title":"Mesoporous silica nanoparticles as a gene delivery platform for cancer therapy","volume":"15","author":"Khaliq","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.critrevonc.2026.105449_bib51","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.arabjc.2017.05.011","article-title":"Nanoparticles: properties, applications and toxicities","volume":"12","author":"Khan","year":"2019","journal-title":"Arab. J. Chem."},{"key":"10.1016\/j.critrevonc.2026.105449_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.112951","article-title":"Biomedical applications of metallic nanoparticles in cancer: Current status and future perspectives","volume":"150","author":"Khursheed","year":"2022","journal-title":"Biomed. & Pharmacother."},{"key":"10.1016\/j.critrevonc.2026.105449_bib53","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1166\/jbn.2014.1928","article-title":"siRNA-based therapies for pulmonary diseases","volume":"10","author":"Koli","year":"2014","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.critrevonc.2026.105449_bib54","doi-asserted-by":"crossref","first-page":"804","DOI":"10.3390\/cancers13040804","article-title":"Targeted therapy in advanced and metastatic non-small cell lung cancer. An update on treatment of the most important actionable oncogenic driver alterations","volume":"13","author":"K\u00f6nig","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105449_bib55","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.3390\/pharmaceutics14081579","article-title":"Application of mesoporous silica nanoparticles in cancer therapy and delivery of repurposed anthelmintics for cancer therapy","volume":"14","author":"Koohi Moftakhari Esfahani","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.critrevonc.2026.105449_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.114038","article-title":"Nanoparticles for local delivery of siRNA in lung therapy","volume":"179","author":"Kubczak","year":"2021","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.critrevonc.2026.105449_bib57","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1677","article-title":"A review on <scp>RNAi<\/scp> therapy for <scp>NSCLC<\/scp>: Opportunities and challenges","volume":"13","author":"Kumar","year":"2021","journal-title":"WIREs Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.critrevonc.2026.105449_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.115049","article-title":"Biosafety of mesoporous silica nanoparticles; towards clinical translation","volume":"201","author":"L\u00e9rida-Viso","year":"2023","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.critrevonc.2026.105449_bib59","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.2147\/OTT.S164574","article-title":"Adenosquamous carcinoma of the lung","volume":"11","author":"Li","year":"2018","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.critrevonc.2026.105449_bib60","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1089\/nat.2021.0002","article-title":"Non-small-cell lung cancer regression by siRNA delivered through exosomes that display EGFR RNA aptamer","volume":"31","author":"Li","year":"2021","journal-title":"Nucleic Acid. Ther."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105449_bib61","doi-asserted-by":"crossref","first-page":"e35628","DOI":"10.1371\/journal.pone.0035628","article-title":"A Redox-Sensitive Luciferase Assay for Determining the Localization and Topology of Endoplasmic Reticulum Proteins","volume":"7","author":"Li","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.critrevonc.2026.105449_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2017.00182","article-title":"Quantum dots-siRNA nanoplexes for gene silencing in central nervous system tumor cells","volume":"8","author":"Lin","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.critrevonc.2026.105449_bib63","doi-asserted-by":"crossref","first-page":"102223","DOI":"10.1016\/j.mtbio.2025.102223","article-title":"Mesoporous silica nanoparticle-based nanomedicine: Preparation, functional modification, and theranostic applications","volume":"34","author":"Liu","year":"2025","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.critrevonc.2026.105449_bib64","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1080\/17425247.2018.1517744","article-title":"RNAi-based therapeutics for lung cancer: biomarkers, microRNAs, and nanocarriers","volume":"15","author":"Magalh\u00e3es","year":"2018","journal-title":"Expert. Opin. Drug. Deliv."},{"key":"10.1016\/j.critrevonc.2026.105449_bib65","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1089\/jamp.2011-0966","article-title":"Characterization and application of a nose-only exposure chamber for inhalation delivery of liposomal drugs and nucleic acids to mice","volume":"26","author":"Mainelis","year":"2013","journal-title":"J. Aerosol Med. Pulm. Drug. Deliv."},{"key":"10.1016\/j.critrevonc.2026.105449_bib66","first-page":"620","article-title":"Clinical insights into small cell lung cancer: tumor heterogeneity, diagnosis, therapy, and future directions","volume":"73","author":"Megyesfalvi","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2026.105449_bib67","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.addr.2014.05.018","article-title":"siRNA Delivery to the lung: What's new?","volume":"75","author":"Merkel","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.critrevonc.2026.105449_bib68","doi-asserted-by":"crossref","first-page":"152","DOI":"10.7150\/ntno.79050","article-title":"Gold nanoparticles conjugated with dendrigraft poly-l-lysine and folate-targeted poly(ethylene glycol) for siRNA delivery to prostate cancer","volume":"7","author":"Minassian","year":"2023","journal-title":"Nanotheranostics"},{"key":"10.1016\/j.critrevonc.2026.105449_bib69","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1039\/C5NR06246B","article-title":"Highly efficient siRNA delivery from core\u2013shell mesoporous silica nanoparticles with multifunctional polymer caps","volume":"8","author":"M\u00f6ller","year":"2016","journal-title":"Nanoscale"},{"key":"10.1016\/j.critrevonc.2026.105449_bib70","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2024.1393646","article-title":"Principle, application and challenges of development siRNA-based therapeutics against bacterial and viral infections: a comprehensive review","volume":"15","author":"Motamedi","year":"2024","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.critrevonc.2026.105449_bib71","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1172\/JCI23043","article-title":"Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer","volume":"115","author":"Nogawa","year":"2005","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.critrevonc.2026.105449_bib72","doi-asserted-by":"crossref","first-page":"16308","DOI":"10.1021\/acsnano.3c07621","article-title":"Future of mesoporous silica nanoparticles in nanomedicine: protocol for reproducible synthesis, characterization, lipid coating, and loading of therapeutics (chemotherapeutic, proteins, siRNA and mRNA)","volume":"17","author":"Noureddine","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.critrevonc.2026.105449_bib73","doi-asserted-by":"crossref","first-page":"5917","DOI":"10.1158\/1538-7445.AM2018-5917","article-title":"Abstract 5917: A novel lipid nanoparticle (NBF-006) encapsulating glutathione S-transferase P (GSTP) siRNA for the treatment of KRAS-driven non-small cell lung cancer","volume":"78","author":"O\u2019Brien*","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105449_bib74","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1158\/0008-5472.CAN-07-5003","article-title":"Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth","volume":"68","author":"Ohta","year":"2008","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105449_bib75","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1248\/bpb.b13-00167","article-title":"Gene Silencing in a Mouse Lung Metastasis Model by an Inhalable Dry Small Interfering RNA Powder Prepared Using the Supercritical Carbon Dioxide Technique","volume":"36","author":"Okuda","year":"2013","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.critrevonc.2026.105449_bib76","first-page":"S108","article-title":"Pancoast tumors: characteristics and preoperative assessment","volume":"6 1","author":"Panagopoulos","year":"2014","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.critrevonc.2026.105449_bib77","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-21601-w","article-title":"Overcoming the non-kinetic activity of EGFR1 using multi-functionalized mesoporous silica nanocarrier for in vitro delivery of siRNA","volume":"12","author":"Parnian","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2026.105449_bib78","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-76332-7","article-title":"Pulmonary surfactant inhibition of nanoparticle uptake by alveolar epithelial cells","volume":"10","author":"Radiom","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2026.105449_bib79","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1158\/1535-7163.MCT-19-1095","article-title":"Inhibition of tumor cell growth and cancer stem cell expansion by a bispecific antibody targeting EGFR and HER3","volume":"19","author":"Rau","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2026.105449_bib80","doi-asserted-by":"crossref","first-page":"4705","DOI":"10.3390\/cancers13184705","article-title":"Current landscape of non-small cell lung cancer: epidemiology, histological classification, targeted therapies, and immunotherapy","volume":"13","author":"Rodak","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105449_bib81","doi-asserted-by":"crossref","first-page":"761","DOI":"10.2217\/17435889.3.6.761","article-title":"Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer","volume":"3","author":"Saad","year":"2008","journal-title":"Nanomedicine"},{"key":"10.1016\/j.critrevonc.2026.105449_bib82","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.3390\/cells10081879","article-title":"Role of NRF2 in lung cancer","volume":"10","author":"S\u00e1nchez-Ortega","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.critrevonc.2026.105449_bib83","doi-asserted-by":"crossref","DOI":"10.1002\/wrna.1581","article-title":"Understanding and targeting the disease-related RNA binding protein human antigen R (HuR)","volume":"11","author":"Schultz","year":"2020","journal-title":"WIREs RNA"},{"key":"10.1016\/j.critrevonc.2026.105449_bib84","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0005-2736(00)00343-6","article-title":"Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures","volume":"1510","author":"Semple","year":"2001","journal-title":"Biochim. Biophys. Acta (BBA) - Biomembr."},{"issue":"33","key":"10.1016\/j.critrevonc.2026.105449_bib85","doi-asserted-by":"crossref","first-page":"8613","DOI":"10.1016\/j.biomaterials.2012.08.007","article-title":"Co-delivery of paclitaxel and survivin shRNA by pluronic P85-PEI\/TPGS complex nanoparticles to overcome drug resistance in lung cancer","volume":"33","author":"Shen","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.critrevonc.2026.105449_bib86","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1369\/0022155411410885","article-title":"Biodistribution of small interfering RNA at the organ and cellular levels after lipid nanoparticle-mediated delivery","volume":"59","author":"Shi","year":"2011","journal-title":"J. Histochem. & Cytochem."},{"key":"10.1016\/j.critrevonc.2026.105449_bib87","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/mt.2013.10","article-title":"Enhanced intrapulmonary delivery of anticancer siRNA for lung cancer therapy using cationic ethylphosphocholine-based nanolipoplexes","volume":"21","author":"Shim","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.critrevonc.2026.105449_bib88","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/j.1440-1827.2011.02730.x","article-title":"A clinicopathological and immunohistological re-evaluation of adenosquamous carcinoma of the lung","volume":"61","author":"Shimoji","year":"2011","journal-title":"Pathol. Int."},{"key":"10.1016\/j.critrevonc.2026.105449_bib89","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/modpathol.2012.158","article-title":"Thymidylate synthase expression and molecular alterations in adenosquamous carcinoma of the lung","volume":"26","author":"Shu","year":"2013","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.critrevonc.2026.105449_bib90","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.3390\/nano12162826","article-title":"Recent advances in functionalized nanoparticles in cancer theranostics","volume":"12","author":"Siddique","year":"2022","journal-title":"Nanomaterials"},{"key":"10.1016\/j.critrevonc.2026.105449_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.jgeb.2025.100484","article-title":"Small interfering RNA: from designing to therapeutic in cancer","volume":"23","author":"Singh","year":"2025","journal-title":"J. Genet. Eng. Biotechnol."},{"key":"10.1016\/j.critrevonc.2026.105449_bib92","first-page":"592","article-title":"Characterization of modified mesoporous silica nanoparticles as vectors for siRNA delivery","volume":"13","author":"Slita","year":"2018","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.critrevonc.2026.105449_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109561","article-title":"Folic acid (FA)-conjugated mesoporous silica nanoparticles combined with MRP-1 siRNA improves the suppressive effects of myricetin on non-small cell lung cancer (NSCLC)","volume":"125","author":"Song","year":"2020","journal-title":"Biomed. & Pharmacother."},{"key":"10.1016\/j.critrevonc.2026.105449_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmpk.2021.100424","article-title":"Difference in the lipid nanoparticle technology employed in three approved siRNA (Patisiran) and mRNA (COVID-19 vaccine) drugs","volume":"41","author":"Suzuki","year":"2021","journal-title":"Drug. Metab. Pharmacokinet."},{"key":"10.1016\/j.critrevonc.2026.105449_bib95","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.00741","article-title":"Targeted therapies and biomarkers in small cell lung cancer","volume":"10","author":"Taniguchi","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105449_bib96","doi-asserted-by":"crossref","first-page":"900","DOI":"10.3109\/1061186X.2011.622404","article-title":"Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA","volume":"19","author":"Taratula","year":"2011","journal-title":"J. Drug. Target."},{"key":"10.1016\/j.critrevonc.2026.105449_bib97","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2013.45","article-title":"Therapeutic silencing of Bcl-2 by systemically administered siRNA nanotherapeutics inhibits tumor growth by autophagy and apoptosis and enhances the efficacy of chemotherapy in orthotopic xenograft models of ER (\u2212) and ER (+) breast cancer","volume":"2","author":"Tekedereli","year":"2013","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.critrevonc.2026.105449_bib98","doi-asserted-by":"crossref","DOI":"10.1098\/rsos.220013","article-title":"Mesoporous silica nanocarriers as drug delivery systems for anti-tubercular agents: a review","volume":"9","author":"Tella","year":"2022","journal-title":"R. Soc. Open. Sci."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105449_bib99","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1166\/jbn.2012.1419","article-title":"Enhancement of Cisplatin Sensitivity in Lung Cancer Xenografts by Liposome-Mediated Delivery of the Plasmid Expressing Small Hairpin RNA Targeting Survivin","volume":"8","author":"Tian","year":"2012","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.critrevonc.2026.105449_bib100","series-title":"Gold Nanoparticles for Drug Delivery","first-page":"141","article-title":"Gold nanoparticles for delivery of nucleic acid constructs for cancer treatment","author":"Truong","year":"2024"},{"key":"10.1016\/j.critrevonc.2026.105449_bib101","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.1016\/j.biomaterials.2009.03.010","article-title":"The use of biotinylated-EGF-modified gelatin nanoparticle carrier to enhance cisplatin accumulation in cancerous lungs via inhalation","volume":"30","author":"Tseng","year":"2009","journal-title":"Biomaterials"},{"key":"10.1016\/j.critrevonc.2026.105449_bib102","article-title":"Nanoparticle-mediated delivery of siRNA: targeting gene silencing in cancer therapy","volume":"109","author":"Udappusamy","year":"2025","journal-title":"J. Drug. Deliv. Sci. Technol."},{"key":"10.1016\/j.critrevonc.2026.105449_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2019.143997","article-title":"Akt1 and Jak1 siRNA based silencing effects on the proliferation and apoptosis in head and neck squamous cell carcinoma","volume":"714","author":"Vakili Saatloo","year":"2019","journal-title":"Gene"},{"key":"10.1016\/j.critrevonc.2026.105449_bib104","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15071932","article-title":"Functionalized metal nanoparticles in cancer therapy","volume":"15","author":"Villalobos Guti\u00e9rrez","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.critrevonc.2026.105449_bib105","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S0002-9440(10)65653-2","article-title":"Typical and atypical carcinoid tumors of the lung are characterized by 11q deletions as detected by comparative genomic hybridization","volume":"153","author":"Walch","year":"1998","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.critrevonc.2026.105449_bib106","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.bbrc.2011.06.019","article-title":"Tumor-targeting magnetic lipoplex delivery of short hairpin RNA suppresses IGF-1R overexpression of lung adenocarcinoma A549 cells in vitro and in vivo","volume":"410","author":"Wang","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.critrevonc.2026.105449_bib107","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1208\/s12248-010-9210-4","article-title":"Delivery of siRNA therapeutics: barriers and carriers","volume":"12","author":"Wang","year":"2010","journal-title":"AAPS J."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105449_bib108","doi-asserted-by":"crossref","first-page":"4308","DOI":"10.1021\/acsami.9b21214","article-title":"Endosomolytic and Tumor-Penetrating Mesoporous Silica Nanoparticles for siRNA\/miRNA Combination Cancer Therapy","volume":"12","author":"Wang","year":"2020","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.critrevonc.2026.105449_bib109","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1166\/jbn.2016.2217","article-title":"A gold nanoparticle platform for the delivery of functional TGF-<I>\u03b2<\/I>1 siRNA into cancer cells","volume":"12","author":"Wu","year":"2016","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.critrevonc.2026.105449_bib110","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.3390\/pharmaceutics15102483","article-title":"Recent advances in mesoporous silica nanoparticles delivering siRNA for cancer treatment","volume":"15","author":"Xie","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.critrevonc.2026.105449_bib111","doi-asserted-by":"crossref","first-page":"L801","DOI":"10.1152\/ajplung.00108.2019","article-title":"Blockade of endothelial, but not epithelial, cell expression of PD-L1 following severe shock attenuates the development of indirect acute lung injury in mice","volume":"318","author":"Xu","year":"2020","journal-title":"Am. J. Physiol. -Lung Cell. Mol. Physiol."},{"key":"10.1016\/j.critrevonc.2026.105449_bib112","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12951-020-00759-3","article-title":"Au-siRNA@ aptamer nanocages as a high-efficiency drug and gene delivery system for targeted lung cancer therapy","volume":"19","author":"Yang","year":"2021","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.critrevonc.2026.105449_bib113","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1021\/mp300152v","article-title":"Nanoparticle delivery of pooled siRNA for effective treatment of non-small cell lung caner","volume":"9","author":"Yang","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.critrevonc.2026.105449_bib114","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.addr.2020.07.022","article-title":"Recent advances in siRNA delivery mediated by lipid-based nanoparticles","volume":"154\u2013155","author":"Yonezawa","year":"2020","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.critrevonc.2026.105449_bib115","doi-asserted-by":"crossref","first-page":"44","DOI":"10.14356\/kona.2017005","article-title":"Aerosol delivery of siRNA to the lungs. Part 2: nanocarrier-based delivery systems","volume":"34","author":"Youngren-Ortiz","year":"2017","journal-title":"KONA Powder Part. J."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105449_bib116","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1016\/j.biomaterials.2012.12.042","article-title":"Induction of apoptosis in non-small cell lung cancer by downregulation of MDM2 using pH-responsive PMPC-b-PDPA\/siRNA complex nanoparticles","volume":"34","author":"Yu","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.critrevonc.2026.105449_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117325","article-title":"Nuclear factor erythroid 2 (NF-E2)-related factor 2 (Nrf2) in non-small cell lung cancer","volume":"254","author":"Zeng","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.critrevonc.2026.105449_bib118","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1186\/s12951-025-03508-6","article-title":"Cancer cell membrane-camouflaged pH-responsive nanoparticles for enhancing siRNA effect and synergistic anti-tumor therapy","volume":"23","author":"Zhang","year":"2025","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.critrevonc.2026.105449_bib119","doi-asserted-by":"crossref","first-page":"31273","DOI":"10.1021\/acsami.3c05007","article-title":"Inhalable siRNA nanoparticles for enhanced tumor-targeting treatment of KRAS -mutant non-small-cell lung cancer","volume":"15","author":"Zhao","year":"2023","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.critrevonc.2026.105449_bib120","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1039\/b601381c","article-title":"PAMAM dendrimers for efficient siRNA delivery and potent gene silencing","author":"Zhou","year":"2006","journal-title":"Chem. Commun."},{"key":"10.1016\/j.critrevonc.2026.105449_bib121","doi-asserted-by":"crossref","first-page":"11449","DOI":"10.1073\/pnas.1411393111","article-title":"Correlating animal and human phase Ia\/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA","volume":"111","author":"Zuckerman","year":"2014","journal-title":"Proc. Natl. Acad. Sci."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003367?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003367?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:46:24Z","timestamp":1793943984000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826003367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":121,"alternative-id":["S1040842826003367"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105449","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted knockdown: siRNA delivery to lung cancer via mesoporous silica nanoparticles","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105449","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105449"}}